-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 8, Sino Biopharmaceutical issued an announcement that the drug "Fosapitant Dimeglumine for Injection" (trade name: Shanqi) developed by the group to prevent nausea and vomiting caused by chemotherapy has been approved by the U.
Data show that fosapitan for injection is a neurokinin-1 (NK-1) receptor antagonist and a prodrug of aprepitant, which is clinically used to prevent nausea caused by chemotherapeutics.
Sales of fosapitan and dimeglumine injections in public medical institutions in China
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
Source: One-click search on Mi Nei.
In terms of consistency evaluation, only Jiangsu Hausen Pharmaceuticals and Qilu Pharmaceuticals have been approved for 3 types of imitations, and they are deemed to have been reviewed.
China Biopharmaceuticals stated that the approval of fosapitant dimeglumine for injection in the United States is another achievement of the group's internationalization strategy, which once again proves the group's determination and ability to enter the overseas high-end market.
Source: Listed company announcement, Mi Neiwang database
